|
esophageal squamous cell carcinoma |
38 |
|
humans |
35 |
|
esophageal cancer |
32 |
|
male |
32 |
|
female |
30 |
|
middle aged |
29 |
|
aged |
27 |
|
gastric cancer |
25 |
|
metastasis |
24 |
|
prognosis |
22 |
|
escc |
20 |
|
adult |
18 |
|
esophageal neoplasms - genetics - metabolism - pathology |
18 |
|
esophagectomy |
17 |
|
neoadjuvant therapy |
17 |
|
carcinoma, squamous cell - genetics - metabolism - pathology |
16 |
|
medical sciences |
16 |
|
animals |
15 |
|
cell line, tumor |
15 |
|
mice |
15 |
|
oesophageal squamous cell carcinoma |
15 |
|
covid-19 |
14 |
|
dna methylation |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
oesophageal cancer |
14 |
|
replication |
14 |
|
sars-cov |
14 |
|
apoptosis |
13 |
|
emt |
13 |
|
esophageal squamous cell carcinoma (escc) |
13 |
|
immunohistochemistry |
13 |
|
lymphatic metastasis |
13 |
|
neoplasm staging |
13 |
|
reverse transcriptase polymerase chain reaction |
13 |
|
aged, 80 and over |
12 |
|
biomarker |
12 |
|
chemoradiotherapy |
12 |
|
neoplasm transplantation |
12 |
|
signal transduction |
12 |
|
squamous cell carcinoma |
12 |
|
tissue microarray |
12 |
|
blotting, western |
11 |
|
enzyme-linked immunosorbent assay |
11 |
|
esophageal carcinoma |
11 |
|
gastroenterology |
11 |
|
mice, nude |
11 |
|
nasopharyngeal carcinoma (npc) |
11 |
|
nidogen-2 (nid2) |
11 |
|
promoter hypermethylation |
11 |
|
tumor cells, cultured |
11 |
|
arhgap fusions |
10 |
|
biobank |
10 |
|
cadherins - blood |
10 |
|
chemoresistance |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
esophageal neoplasms - genetics |
10 |
|
extracellular matrix protein |
10 |
|
gene expression profiling |
10 |
|
gene expression regulation, neoplastic |
10 |
|
heterogeneity |
10 |
|
oesophagectomy |
10 |
|
organoid culture |
10 |
|
predictive value of tests |
10 |
|
prognostic marker |
10 |
|
rhoa mutations |
10 |
|
surgery |
10 |
|
survival |
10 |
|
survival rate |
10 |
|
transcriptome sequencing |
10 |
|
treatment outcome |
10 |
|
tumor suppression |
10 |
|
tumor suppressor |
10 |
|
whole-exome sequencing |
10 |
|
adam proteins - biosynthesis - genetics - metabolism |
9 |
|
carcinoma, squamous cell - genetics |
9 |
|
carcinoma, squamous cell - genetics - pathology |
9 |
|
combined modality therapy |
9 |
|
dual specificity phosphatase 6 - genetics - metabolism |
9 |
|
dual-specificity phosphatase 6 (dusp6) |
9 |
|
endothelial cells - cytology |
9 |
|
enzyme activation |
9 |
|
epithelial-mesenchymal transition |
9 |
|
esophageal neoplasms - blood supply - enzymology - genetics |
9 |
|
esophageal neoplasms - genetics - pathology |
9 |
|
helicobacter pylori |
9 |
|
hong kong |
9 |
|
in situ hybridization, fluorescence |
9 |
|
karyotyping |
9 |
|
nasopharyngeal neoplasms - blood supply - enzymology - genetics |
9 |
|
nasopharyngeal neoplasms - genetics - metabolism - pathology |
9 |
|
neoadjuvant chemoradiotherapy |
9 |
|
promoter regions, genetic - genetics |
9 |
|
survival analysis |
9 |
|
telomerase |
9 |
|
tumor markers, biological - blood |
9 |
|
tumor suppressor gene |
9 |
|
cell proliferation |
8 |
|
chinese |
8 |
|
chromosome mapping |
8 |
|
e-cadherin |
8 |
|
esophagectomy - methods |
8 |
|
etv4 |
8 |
|
gene expression regulation, neoplastic - drug effects |
8 |
|
longitudinal real-time monitoring |
8 |
|
non-invasive biomarker |
8 |
|
nrp2 |
8 |
|
nucleic acid hybridization |
8 |
|
promoter regions, genetic |
8 |
|
proportional hazards models |
8 |
|
prospective studies |
8 |
|
rna‐seq |
8 |
|
statistics, nonparametric |
8 |
|
transfection |
8 |
|
adenocarcinoma - blood - diagnosis |
7 |
|
advanced escc |
7 |
|
aneuploidy |
7 |
|
asian continental ancestry group |
7 |
|
azygos vein blood |
7 |
|
base sequence |
7 |
|
carcinogenicity tests |
7 |
|
carcinoma, squamous cell - genetics - mortality - pathology |
7 |
|
cell movement |
7 |
|
cell-free dna |
7 |
|
chemoprevention |
7 |
|
circulating mirna |
7 |
|
circulating tumor cells |
7 |
|
circulating tumor cells (ctc) |
7 |
|
ctc clusters |
7 |
|
ctc enumeration |
7 |
|
diagnosis and prognosis |
7 |
|
early prediction |
7 |
|
epidemiology |
7 |
|
esophageal |
7 |
|
esophageal neoplasm |
7 |
|
esophageal neoplasms - genetics - mortality - pathology |
7 |
|
gastrointestinal bleeding |
7 |
|
genes, tumor suppressor |
7 |
|
id‐1 |
7 |
|
immortal time bias |
7 |
|
invasion |
7 |
|
liquid biopsy |
7 |
|
methylation |
7 |
|
microrna therapy |
7 |
|
mir‐338‐5p |
7 |
|
molecular sequence data |
7 |
|
nonsteroidal anti-inflammatory drugs |
7 |
|
nuclear proteins - biosynthesis - genetics |
7 |
|
nucleosome organization |
7 |
|
oligonucleotide array sequence analysis |
7 |
|
overexpression |
7 |
|
p38 signaling |
7 |
|
rassf1a |
7 |
|
stat5a |
7 |
|
stomach neoplasms - blood - diagnosis |
7 |
|
tissue array analysis |
7 |
|
tumor markers, biological - genetics |
7 |
|
tumor stem cell assay |
7 |
|
tumor suppressor proteins - genetics |
7 |
|
whole‐exome sequencing |
7 |
|
znf750 mutation |
7 |
|
abdominal surgery |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
alleles |
6 |
|
ampk |
6 |
|
antiangiogenesis |
6 |
|
apoptosis - genetics |
6 |
|
cancer progression |
6 |
|
carcinoma, squamous cell - metabolism - mortality |
6 |
|
carcinoma, squamous cell - mortality - surgery |
6 |
|
cardiac surgery |
6 |
|
cell line, transformed |
6 |
|
chemotherapy |
6 |
|
chi-square distribution |
6 |
|
chromosome aberrations |
6 |
|
chromosome deletion |
6 |
|
chromosome segregation |
6 |
|
chromosomes, human, pair 13 - genetics |
6 |
|
computed tomography |
6 |
|
crip2 |
6 |
|
ctc |
6 |
|
deep learning |
6 |
|
deoxycytidine - pharmacology |
6 |
|
dna methylation - drug effects |
6 |
|
epithelial cells - drug effects - pathology |
6 |
|
esophageal neoplasms - chemistry - genetics - pathology |
6 |
|
esophageal neoplasms - metabolism - mortality |
6 |
|
esophageal neoplasms - mortality - surgery |
6 |
|
esophagus - pathology |
6 |
|
flow cytometry |
6 |
|
gastric carcinoma |
6 |
|
gene amplification |
6 |
|
gene expression |
6 |
|
general surgery |
6 |
|
genes, tumor suppressor - physiology |
6 |
|
genome, human - genetics |
6 |
|
hospital mortality |
6 |
|
hydroxamic acids - pharmacology |
6 |
|
hypermethylation |
6 |
|
latent tgf-beta binding proteins - genetics - metabolism |
6 |
|
lim domain proteins - genetics - metabolism |
6 |
|
loh |
6 |
|
ltbp-2 |
6 |
|
lymphadenectomy |
6 |
|
median survival after surgery |
6 |
|
medicine & public health |
6 |
|
microarray analysis |
6 |
|
microcell-mediated chromosome transfer |
6 |
|
microsatellite repeats - genetics |
6 |
|
migration |
6 |
|
mortality |
6 |
|
mutation |
6 |
|
nidogen-2 |
6 |
|
nodal metastasis |
6 |
|
nuclear survivin |
6 |
|
oesophagus |
6 |
|
palliative care |
6 |
|
pathological stage |
6 |
|
phosphorylated ron |
6 |
|
poor prognostic marker |
6 |
|
radiogenomic |
6 |
|
radiomics |
6 |
|
radiotherapy |
6 |
|
serum biomarker |
6 |
|
silibinin |
6 |
|
targeted therapy |
6 |
|
thoracic surgery |
6 |
|
thrombospondins - genetics - metabolism |
6 |
|
transplantation, heterologous |
6 |
|
tumor suppressor proteins - genetics - metabolism |
6 |
|
tumorigenicity |
6 |
|
twist1 |
6 |
|
vascular surgery |
6 |
|
xenograft |
6 |
|
14-3-3σ |
5 |
|
3p21 |
5 |
|
adam proteins - genetics |
5 |
|
adamts9 |
5 |
|
alport's syndrome |
5 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
5 |
|
barrett's esophagus |
5 |
|
basaloid squamous carcinoma |
5 |
|
brca2 |
5 |
|
carcinoma, squamous cell - epidemiology - genetics - pathology |
5 |
|
carcinoma, squamous cell - ethnology - genetics - pathology |
5 |
|
carcinoma, squamous cell - ethnology - metabolism - pathology |
5 |
|
cardia |
5 |
|
cell division |
5 |
|
cell proliferation - drug effects |
5 |
|
cell transformation, neoplastic |
5 |
|
cell transformation, neoplastic - genetics - metabolism - pathology |
5 |
|
chemoradiation response |
5 |
|
chemotherapy, adjuvant |
5 |
|
china - ethnology |
5 |
|
chromosome 3 |
5 |
|
chromosome aberrations - genetics |
5 |
|
chromosomes, human - ultrastructure |
5 |
|
chromosomes, human, pair 3 |
5 |
|
chromosomes, human, pair 5 |
5 |
|
cisplatin |
5 |
|
comparative genomic hybridization |
5 |
|
dna |
5 |
|
dna, complementary - genetics |
5 |
|
enzyme inhibitors - pharmacology |
5 |
|
epithelium - metabolism - pathology |
5 |
|
esophageal cancer surgery |
5 |
|
esophageal cancer susceptibility gene |
5 |
|
esophageal leiomyoma |
5 |
|
esophageal neoplasms |
5 |
|
esophageal neoplasms - epidemiology - genetics - pathology |
5 |
|
esophageal neoplasms - ethnology - genetics - pathology |
5 |
|
esophageal neoplasms - ethnology - metabolism - pathology |
5 |
|
esophagus |
5 |
|
esophagus - metabolism - pathology - physiology |
5 |
|
fluorine-18-fluorodeoxyglucose |
5 |
|
fruit - chemistry |
5 |
|
gene expression regulation, enzymologic - drug effects |
5 |
|
gene over-expression |
5 |
|
gene overexpression |
5 |
|
genes, neoplasm |
5 |
|
gleditsia - chemistry |
5 |
|
hmgb1 |
5 |
|
immortalization |
5 |
|
karyotype |
5 |
|
keratins - analysis |
5 |
|
la-tam |
5 |
|
loss‐of‐function mutations |
5 |
|
lymph node excision |
5 |
|
lymph node metastasis |
5 |
|
lymph nodes - pathology |
5 |
|
mice, inbred balb c |
5 |
|
microarray |
5 |
|
midkine |
5 |
|
mir-193b |
5 |
|
morbidity |
5 |
|
multi-omics study |
5 |
|
multimodality treatment |
5 |
|
neoadjuvant chemoradiation |
5 |
|
neoplasm proteins - analysis |
5 |
|
neoplasm proteins - genetics |
5 |
|
neoplasm proteins - genetics - metabolism |
5 |
|
neoplasms, squamous cell - genetics - metabolism - pathology |
5 |
|
nih 3t3 cells |
5 |
|
oesophageal carcinoma |
5 |
|
oncogenes - physiology |
5 |
|
oncogenic expression |
5 |
|
p16 ink4a |
5 |
|
plant extracts - pharmacology |
5 |
|
positron-emission tomography |
5 |
|
protein translation |
5 |
|
retrotransposon insertion |
5 |
|
sequence analysis, dna |
5 |
|
serglycin |
5 |
|
serum micrornas |
5 |
|
spatial analysis |
5 |
|
stomach neoplasms - diagnosis - genetics - mortality |
5 |
|
synthetic lethality |
5 |
|
telomerase - antagonists & inhibitors - genetics - metabolism |
5 |
|
telomerase - biosynthesis - genetics |
5 |
|
tomography, x-ray computed |
5 |
|
transforming capacity |
5 |
|
tumor cells, cultured - chemistry - pathology |
5 |
|
tumor cells, cultured - pathology |
5 |
|
tumour marker |
5 |
|
xpa |
5 |
|
7q22 |
4 |
|
acp |
4 |
|
active surveillance |
4 |
|
acute inflammatory response |
4 |
|
acute-on-chronic liver failure |
4 |
|
adenocarcinoma - diagnosis - genetics - mortality |
4 |
|
adenocarcinoma - etiology - genetics - metabolism |
4 |
|
airway obstruction - therapy |
4 |
|
algorithms |
4 |
|
amino acid sequence |
4 |
|
antibodies, bispecific |
4 |
|
antibody therapy |
4 |
|
antigens, cd - analysis - genetics |
4 |
|
antigens, nuclear |
4 |
|
antigens,-cd95-metabolism |
4 |
|
antineoplastic agents |
4 |
|
antineoplastic agents - therapeutic use |
4 |
|
aspirin |
4 |
|
bone marrow-derived cells |
4 |
|
cadherins - metabolism |
4 |
|
calcium channel blockers |
4 |
|
cancer cell |
4 |
|
cancer growth |
4 |
|
cancer inhibition |
4 |
|
cancer invasion |
4 |
|
cancer resistance |
4 |
|
cancer surgery |
4 |
|
carcinoembryonic antigen |
4 |
|
carcinoma, squamous cell - chemistry - genetics - immunology - secondary |
4 |
|
carcinoma, squamous cell - diagnosis - metabolism - secondary |
4 |
|
carcinoma, squamous cell - genetics - metabolism |
4 |
|
carcinoma, squamous cell - metabolism |
4 |
|
carcinoma, squamous cell - metabolism - secondary - surgery |
4 |
|
carcinoma, squamous cell - mortality - pathology - surgery - therapy |
4 |
|
carcinoma, squamous cell - mortality - pathology - therapy |
4 |
|
carcinoma, squamous cell - mortality - therapy |
4 |
|
carcinoma, squamous cell - pathology - therapy |
4 |
|
carcinoma,-squamous-cell-metabolism |
4 |
|
cardiopulmonary resuscitation |
4 |
|
cardiopulmonary resuscitation - adverse effects |
4 |
|
ccl |
4 |
|
cell adhesion |
4 |
|
cell adhesion molecules - metabolism |
4 |
|
cell membrane - metabolism |
4 |
|
cell nucleus - metabolism |
4 |
|
cell survival |
4 |
|
cervical lymph node metastases |
4 |
|
chemokine (c-c motif) ligand |
4 |
|
chemokines, cc - genetics - immunology |
4 |
|
china |
4 |
|
cholecystectomy |
4 |
|
chromosome 9 |
4 |
|
chromosomes, human, pair 18 - genetics |
4 |
|
chromosomes, human, pair 7 |
4 |
|
chromosomes, human, pair 9 - genetics |
4 |
|
ci |
4 |
|
cohort studies |
4 |
|
collagen |
4 |
|
complication |
4 |
|
complications |
4 |
|
confidence interval |
4 |
|
cpr |
4 |
|
cytokines |
4 |
|
cytology and histology |
4 |
|
cytoplasm - metabolism |
4 |
|
deceased donor liver transplant |
4 |
|
deleted in esophageal cancer 1 |
4 |
|
disease progression |
4 |
|
dna microarray |
4 |
|
double endoscope |
4 |
|
down-regulation |
4 |
|
drug combinations |
4 |
|
endoflip |
4 |
|
endoglin |
4 |
|
epithelial cells - pathology |
4 |
|
esophageal neoplasms - diagnosis - metabolism - secondary |
4 |
|
esophageal neoplasms - genetics - metabolism |
4 |
|
esophageal neoplasms - metabolism - pathology - surgery |
4 |
|
esophageal neoplasms - mortality - pathology - surgery |
4 |
|
esophageal neoplasms - mortality - pathology - surgery - therapy |
4 |
|
esophageal neoplasms - mortality - pathology - therapy |
4 |
|
esophageal neoplasms - mortality - therapy |
4 |
|
esophageal neoplasms - pathology - surgery |
4 |
|
esophageal neoplasms - pathology - therapy |
4 |
|
esophageal neoplasms - psychology - surgery |
4 |
|
esophageal neoplasms - surgery |
4 |
|
esophageal perforation |
4 |
|
esophageal-neoplasms-metabolism |
4 |
|
esophagectomy - adverse effects |
4 |
|
exome |
4 |
|
first aid - adverse effects |
4 |
|
fluorescent antibody technique |
4 |
|
gastrectomy |
4 |
|
gastric intestinal metaplasia |
4 |
|
gastric mucosa - physiology |
4 |
|
gastric rupture |
4 |
|
gastritis |
4 |
|
gene expression regulation, neoplastic - immunology |
4 |
|
gene silencing |
4 |
|
genetic susceptibility |
4 |
|
h pylori |
4 |
|
hazard ratio |
4 |
|
heimlich maneuver |
4 |
|
helicobacter |
4 |
|
helicobacter infections - complications |
4 |
|
hmga2 |
4 |
|
hr |
4 |
|
ibd |
4 |
|
id proteins |
4 |
|
ihc |
4 |
|
immunoenzyme techniques |
4 |
|
inherited escc |
4 |
|
inhibitor of differentiation protein 1 - biosynthesis |
4 |
|
inhibitor of differentiation protein 2 - biosynthesis |
4 |
|
inhibitor of differentiation proteins - biosynthesis |
4 |
|
intracellular signaling peptides and proteins - genetics |
4 |
|
kaplan-meier estimate |
4 |
|
ki-67 antigen |
4 |
|
laminin |
4 |
|
liver neoplasms - genetics - metabolism - secondary |
4 |
|
liver transplant |
4 |
|
living donor liver transplant |
4 |
|
loss of heterozygosity |
4 |
|
lung diseases - etiology |
4 |
|
lung neoplasms - genetics - metabolism - secondary |
4 |
|
macrophages - physiology |
4 |
|
matrix metalloproteinase |
4 |
|
membrane glycoproteins - genetics - metabolism |
4 |
|
mice, scid |
4 |
|
microsatellite repeats |
4 |
|
mmp |
4 |
|
models, genetic |
4 |
|
mucosal immunity |
4 |
|
multivariate analysis |
4 |
|
natural orifice translumenal endoscopic surgery |
4 |
|
neck |
4 |
|
neoplasm invasiveness |
4 |
|
neoplasm recurrence, local - blood |
4 |
|
neoplasm staging - methods |
4 |
|
notes |
4 |
|
nuclear proteins - genetics |
4 |
|
oncogene proteins - genetics |
4 |
|
oncology medical sciences |
4 |
|
organoid model |
4 |
|
outcomes |
4 |
|
p120 catenin |
4 |
|
palliative care - methods |
4 |
|
pediatric achalasia |
4 |
|
peg10 |
4 |
|
peroral endoscopic myotomy |
4 |
|
pi3k/akt |
4 |
|
plasmids |
4 |
|
polymerase chain reaction |
4 |
|
prosthesis implantation - instrumentation |
4 |
|
proteoglycans |
4 |
|
proton pump inhibitors |
4 |
|
quality of life |
4 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
|
radiotherapy, adjuvant |
4 |
|
receptors, cell surface - analysis - genetics |
4 |
|
recurrence |
4 |
|
reverse-transcription polymerase chain reaction |
4 |
|
rna interference |
4 |
|
rna, messenger - genetics |
4 |
|
rna, messenger - genetics - metabolism |
4 |
|
rt-pcr |
4 |
|
shank2 |
4 |
|
snp array |
4 |
|
ssc |
4 |
|
staging |
4 |
|
standard saline citrate |
4 |
|
stomach neoplasms - blood - surgery |
4 |
|
stomach neoplasms - etiology - genetics - metabolism |
4 |
|
stomach neoplasms - psychology - surgery |
4 |
|
stomach rupture - etiology |
4 |
|
t-lymphocytes - immunology |
4 |
|
tartrate-resistant acid phosphatase |
4 |
|
thoracic neoplasms - pathology - therapy |
4 |
|
time trend |
4 |
|
transcription factors - genetics |
4 |
|
transforming gene |
4 |
|
transvaginal surgery |
4 |
|
tumor angiogenesis |
4 |
|
tumor differentiation |
4 |
|
tumor growth |
4 |
|
tumor marker |
4 |
|
tumor markers, biological - analysis |
4 |
|
tumor markers, biological - biosynthesis |
4 |
|
tumor markers, biological - biosynthesis - genetics |
4 |
|
tumor microenvironment |
4 |
|
tumor suppressor proteins - analysis - genetics |
4 |
|
tumor-markers,-biological-metabolism |
4 |
|
tumorigenesis |
4 |
|
up-regulation |
4 |
|
uroplakin ia |
4 |
|
vegf receptors |
4 |
|
wound healing |
4 |
|
xenograft model antitumor assays |
4 |
|
accuracy |
3 |
|
achalasia |
3 |
|
adenocarcinoma |
3 |
|
adenocarcinoma - mortality - surgery |
3 |
|
adolescent |
3 |
|
analgesia - methods |
3 |
|
analgesia, patient-controlled |
3 |
|
anastomosis, surgical |
3 |
|
anchorage-independent growth |
3 |
|
aneurysm, infected - etiology - radiography |
3 |
|
anti-bacterial agents - therapeutic use |
3 |
|
anti-ulcer agents - therapeutic use |
3 |
|
antibodies, monoclonal - immunology |
3 |
|
anticancer |
3 |
|
aortic aneurysm, thoracic - microbiology - radiography |
3 |
|
aortic diseases - complications |
3 |
|
aorto-oesophageal fistula |
3 |
|
aspiration |
3 |
|
bacterial artificial chromosome |
3 |
|
biliary obstruction |
3 |
|
bone morphogenetic protein 6 - genetics - metabolism |
3 |
|
bone morphogenetic proteins - genetics - metabolism |
3 |
|
cadherins - genetics |
3 |
|
cancer metastasis |
3 |
|
cancer prognosis |
3 |
|
carcinoma |
3 |
|
carcinoma, basosquamous - metabolism - pathology |
3 |
|
carcinoma, squamous cell - blood - mortality - pathology - therapy |
3 |
|
carcinoma, squamous cell - chemistry - genetics - pathology |
3 |
|
carcinoma, squamous cell - complications - mortality - therapy |
3 |
|
carcinoma, squamous cell - diagnosis - pathology - therapy |
3 |
|
carcinoma, squamous cell - genetics - mortality |
3 |
|
carcinoma, squamous cell - genetics - pathology - surgery |
3 |
|
carcinoma, squamous cell - metabolism - pathology |
3 |
|
carcinoma, squamous cell - mortality - pathology - surgery |
3 |
|
carrier proteins - genetics - metabolism |
3 |
|
cd71 |
3 |
|
cdc25 phosphatases - analysis - genetics |
3 |
|
cell cycle - drug effects |
3 |
|
cell cycle proteins - analysis - genetics |
3 |
|
cell transformation, neoplastic - genetics |
3 |
|
cells, cultured |
3 |
|
cervical esophagus |
3 |
|
chemoradiation |
3 |
|
chemotherapeutic drug responses |
3 |
|
chromosomes |
3 |
|
chromosomes, human, pair 12 - genetics |
3 |
|
clarithromycin - therapeutic use |
3 |
|
clinical article |
3 |
|
colorectal neoplasms - metabolism |
3 |
|
communicable diseases |
3 |
|
complementary dna |
3 |
|
continuous intraoperative nerve monitoring |
3 |
|
coughing |
3 |
|
crispr/cas9 screening |
3 |
|
cyclin d1 - genetics |
3 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
3 |
|
databases, factual |
3 |
|
dec1 |
3 |
|
digestive system surgical procedures - methods |
3 |
|
diploidy |
3 |
|
direct thrombin inhibitor |
3 |
|
disease association |
3 |
|
disease-free survival |
3 |
|
dna - metabolism |
3 |
|
dna fingerprinting |
3 |
|
dna, neoplasm - analysis |
3 |
|
dna-binding proteins - analysis - genetics |
3 |
|
dna-binding proteins - genetics |
3 |
|
dose fractionation |
3 |
|
drainage - methods |
3 |
|
drug administration schedule |
3 |
|
drug therapy, combination |
3 |
|
endoscopes - adverse effects |
3 |
|
endoscopy, digestive system - adverse effects |
3 |
|
endovascular aneurysm stent-graft |
3 |
|
enzyme linked immunosorbent assay |
3 |
|
epigenesis, genetic |
3 |
|
epithelial cells - drug effects - metabolism - pathology |
3 |
|
epithelium - metabolism |
3 |
|
eradication |
3 |
|
esophageal atresia |
3 |
|
esophageal fistula - complications |
3 |
|
esophageal neoplasms - blood - mortality - pathology - therapy |
3 |
|
esophageal neoplasms - complications - mortality - therapy |
3 |
|
esophageal neoplasms - diagnosis - pathology - therapy |
3 |
|
esophageal neoplasms - genetics - pathology - surgery |
3 |
|
esophageal neoplasms - genetics - pathology - virology |
3 |
|
esophageal neoplasms - metabolism - pathology |
3 |
|
esophageal neoplasms - radiography - surgery |
3 |
|
esophageal perforation - complications |
3 |
|
esophagectomy - adverse effects - mortality |
3 |
|
esophagus - cytology - metabolism |
3 |
|
esophagus - injuries |
3 |
|
esophagus - metabolism - pathology |
3 |
|
factor xa inhibitor |
3 |
|
foxo1 |
3 |
|
gastric dysplasia |
3 |
|
gastric pull-up |
3 |
|
genes, p53 - genetics |
3 |
|
genetic markers - genetics |
3 |
|
gist |
3 |
|
gut mucosa |
3 |
|
head and neck cancer |
3 |
|
head and neck neoplasms - complications - mortality - therapy |
3 |
|
heart diseases - etiology |
3 |
|
helicobacter infections - drug therapy |
3 |
|
hong kong - epidemiology |
3 |
|
hpv |
3 |
|
hypopharynx |
3 |
|
iatrogenic disease |
3 |
|
iatrogenic oesophageal perforation |
3 |
|
image processing, computer-assisted |
3 |
|
in situ hybridization, fluorescence - methods |
3 |
|
inhibitor of differentiation protein 1 |
3 |
|
inhibitor of differentiation protein 1 - metabolism |
3 |
|
injections, intravenous |
3 |
|
interleukin-6 |
3 |
|
interleukin-8 - blood - metabolism |
3 |
|
intraoperative complications - epidemiology |
3 |
|
jumonji domain-containing histone demethylases |
3 |
|
laparoscopy |
3 |
|
length of stay |
3 |
|
macrophage migration-inhibitory factors - blood - metabolism |
3 |
|
membrane proteins - analysis - genetics |
3 |
|
meperidine - administration & dosage |
3 |
|
metronidazole - therapeutic use |
3 |
|
micrornas - chemistry - metabolism |
3 |
|
midline incision |
3 |
|
minimally invasive surgery |
3 |
|
mir-1288 |
3 |
|
morphine - administration & dosage |
3 |
|
mucous membrane - pathology |
3 |
|
mutation - genetics |
3 |
|
nasopharyngeal carcinoma |
3 |
|
natural orifice translumenal surgery (notes) |
3 |
|
natural orifice transluminal endoscopic surgery |
3 |
|
neoadjuvant chemoradiation therapy |
3 |
|
neoplasm invasiveness - pathology |
3 |
|
neoplasm recurrence, local |
3 |
|
neoplasms - enzymology - genetics |
3 |
|
neoplasms, multiple primary - mortality - therapy |
3 |
|
neoplasms, second primary - mortality - therapy |
3 |
|
nerve monitoring |
3 |
|
nocodazole - pharmacology |
3 |
|
noncoding rna |
3 |
|
nuclear proteins - immunology |
3 |
|
oesophageal |
3 |
|
omeprazole - therapeutic use |
3 |
|
oncogene proteins, viral - genetics - metabolism |
3 |
|
oncology |
3 |
|
oxidoreductases, n-demethylating - genetics |
3 |
|
oxygen carrier |
3 |
|
papillomaviridae - isolation & purification |
3 |
|
papillomavirus e7 proteins |
3 |
|
pathology |
3 |
|
peritoneoscopy |
3 |
|
peritoneum |
3 |
|
pharyngogastric anastomosis |
3 |
|
pharyngolaryngo-esophagectomy |
3 |
|
pleural drainage |
3 |
|
pneumoperitoneum - etiology - radiography |
3 |
|
polymerase chain reaction - methods |
3 |
|
polymorphism, single-stranded conformational |
3 |
|
porcine model |
3 |
|
postoperative care |
3 |
|
postoperative complication |
3 |
|
postoperative complications - epidemiology |
3 |
|
postoperative complications - mortality |
3 |
|
postoperative stress response |
3 |
|
prostatic neoplasms - metabolism |
3 |
|
protein interactome |
3 |
|
protein-serine-threonine kinases - genetics - metabolism |
3 |
|
proto-oncogene proteins c-fos - analysis - genetics |
3 |
|
proto-oncogene proteins c-met - analysis - genetics |
3 |
|
pylorus - surgery |
3 |
|
radical gastrectomy surgery |
3 |
|
receptor, igf type 1 - metabolism |
3 |
|
reconstructive surgical procedures |
3 |
|
recurrent laryngeal nerve |
3 |
|
repetitive sequences, nucleic acid |
3 |
|
repressor proteins |
3 |
|
repressor proteins - genetics - metabolism |
3 |
|
retrospective studies |
3 |
|
risk factors |
3 |
|
rna, neoplasm - genetics - metabolism |
3 |
|
rna, small interfering |
3 |
|
sirna |
3 |
|
soluble e-cadherin |
3 |
|
spectral karyotyping |
3 |
|
stomach - surgery |
3 |
|
stomach neoplasms - mortality - surgery |
3 |
|
stomach neoplasms - pathology - surgery |
3 |
|
stomach neoplasms - surgery |
3 |
|
stromal tumour |
3 |
|
stump |
3 |
|
subcostal rooftop incision |
3 |
|
survey |
3 |
|
suture techniques |
3 |
|
synchronous or antecedent cancers |
3 |
|
syndrome |
3 |
|
telomerase - genetics |
3 |
|
telomerase - genetics - metabolism |
3 |
|
telomerase - physiology |
3 |
|
thoracic aortic aneurysm |
3 |
|
thoracoscopic esophagectomy |
3 |
|
thoracoscopy |
3 |
|
transanal endoscopic surgery |
3 |
|
transcription factors - analysis - genetics |
3 |
|
transferrin receptor |
3 |
|
transrectal |
3 |
|
transvaginal cholecystectomy |
3 |
|
tumor markers, biological - chemistry - metabolism |
3 |
|
tumor markers, biological - genetics - metabolism |
3 |
|
tumor suppressor protein p53 - analysis |
3 |
|
tumor suppressor protein p53 - genetics - metabolism |
3 |
|
urinary bladder neoplasms - metabolism |
3 |
|
vascular fistula - complications |
3 |
|
yq23 |
3 |
|
3p21.3 |
2 |
|
ac4c modification |
2 |
|
adenocarcinoma - mortality - pathology - surgery |
2 |
|
advantages |
2 |
|
aging |
2 |
|
analgesia, epidural |
2 |
|
anastomosis |
2 |
|
anastomosis leakage |
2 |
|
anastomosis, surgical - adverse effects |
2 |
|
angiomyolipoma |
2 |
|
antibodies, monoclonal - diagnostic use |
2 |
|
asia - epidemiology |
2 |
|
asia-pacific |
2 |
|
asian barrett's consortium |
2 |
|
autonomic nerve tumor |
2 |
|
biocompatible materials |
2 |
|
biomarkers |
2 |
|
blu |
2 |
|
boerhaave’s |
2 |
|
brachytherapy |
2 |
|
bronchial fistula - etiology |
2 |
|
bronchial neoplasms - mortality - radiotherapy - secondary |
2 |
|
calpain 10 |
2 |
|
cancer chemotherapy |
2 |
|
cancer grading |
2 |
|
cancer mortality |
2 |
|
cancer radiotherapy |
2 |
|
cancer staging |
2 |
|
carcinoma - pathology - surgery |
2 |
|
carcinoma, small cell - complications - therapy |
2 |
|
carcinoma, squamous cell - complications - pathology - ultrastructure |
2 |
|
carcinoma, squamous cell - complications - therapy |
2 |
|
carcinoma, squamous cell - drug therapy - metabolism - pathology - surgery |
2 |
|
carcinoma, squamous cell - mortality - pathology |
2 |
|
colon and rectal obstruction |
2 |
|
colorectal neoplasms - complications - mortality - radiography - surgery |
2 |
|
colostomy - instrumentation |
2 |
|
conversion surgery |
2 |
|
conversion therapy |
2 |
|
curcumin |
2 |
|
deglutition disorders - etiology |
2 |
|
deglutition disorders - etiology - therapy |
2 |
|
developing countries |
2 |
|
diagnosis |
2 |
|
differentiation |
2 |
|
disease exacerbation |
2 |
|
diving |
2 |
|
diving - adverse effects |
2 |
|
duodenal ulcer |
2 |
|
endoscopic mucosal resections |
2 |
|
endoscopic submucosal dissection |
2 |
|
endoscopic therapy |
2 |
|
endoscopy, digestive system |
2 |
|
esophageal achalasia |
2 |
|
esophageal adenocarcinoma |
2 |
|
esophageal cancer metastasis |
2 |
|
esophageal motility disorders |
2 |
|
esophageal neoplasms - complications - mortality - physiopathology - therapy |
2 |
|
esophageal neoplasms - complications - pathology - ultrastructure |
2 |
|
esophageal neoplasms - complications - therapy |
2 |
|
esophageal neoplasms - drug therapy - metabolism - pathology - surgery |
2 |
|
esophageal neoplasms - drug therapy - pathology - surgery |
2 |
|
esophageal neoplasms - epidemiology - therapy |
2 |
|
esophageal neoplasms - mortality - pathology |
2 |
|
esophageal perforation - etiology - therapy |
2 |
|
esophagectomy - mortality |
2 |
|
esophagectomy for esophageal cancer |
2 |
|
esophagogastric junction |
2 |
|
esophagogastric junction - pathology - physiopathology |
2 |
|
esophagus - cancer - mortality. |
2 |
|
esophagus - cancer - surgery. |
2 |
|
esophagus - cancer - treatment. |
2 |
|
esophagus - surgery |
2 |
|
evaluation studies as topic |
2 |
|
fatal outcome |
2 |
|
feasibility studies |
2 |
|
foregut surgery |
2 |
|
gastric outlet obstruction - etiology - therapy |
2 |
|
gastrointestinal surgery |
2 |
|
glomerulonephritis, iga - complications - pathology |
2 |
|
grade |
2 |
|
hamartoma |
2 |
|
hematoma |
2 |
|
histology |
2 |
|
iga nephropathy |
2 |
|
incidence |
2 |
|
intervention |
2 |
|
intestinal obstruction - etiology - mortality - radiography - surgery |
2 |
|
intrathoracic anastomotic leak |
2 |
|
ischemic gastric conduit |
2 |
|
ki- 67 |
2 |
|
laparoscopic gastrectomy |
2 |
|
laparotomy |
2 |
|
laser therapy |
2 |
|
lymph node excision - methods |
2 |
|
lysosomal acidification |
2 |
|
mediastinal emphysema - etiology - radiography |
2 |
|
melanoma |
2 |
|
metallic stents |
2 |
|
mib-1 |
2 |
|
mib-1 labelling index |
2 |
|
microscopy, electron |
2 |
|
mie |
2 |
|
minimally invasive surgical approach |
2 |
|
mir-498 |
2 |
|
mitotic index |
2 |
|
modern results |
2 |
|
multidrug resistance |
2 |
|
multimodal treatment |
2 |
|
nat10 |
2 |
|
natural orifice transluminal endoscopic surgery (notes) |
2 |
|
neoplasm proteins - metabolism |
2 |
|
neoplasm recurrence, local - complications - mortality - physiopathology |
2 |
|
nuclear proteins - isolation & purification |
2 |
|
oncogene |
2 |
|
open gastrectomy |
2 |
|
orthotopic route |
2 |
|
orthotopic tumor xenograft |
2 |
|
p-glycoprotein |
2 |
|
p53 |
2 |
|
pacific islands - epidemiology |
2 |
|
palliation |
2 |
|
paraneoplastic |
2 |
|
pathogenesis |
2 |
|
patient selection |
2 |
|
patient-derived tumor xenograft |
2 |
|
perforation |
2 |
|
perforation score |
2 |
|
pharyngolaryngoesophagectomy |
2 |
|
pneumomediastinum, diagnostic |
2 |
|
postoperative complications |
2 |
|
postoperative complications - etiology |
2 |
|
postoperative complications - surgery |
2 |
|
prague criteria |
2 |
|
precancerous condition |
2 |
|
predisposing factors |
2 |
|
preoperative |
2 |
|
proliferating cell nuclear antigen |
2 |
|
proliferating cell nuclear antigen - isolation & purification |
2 |
|
quinoline compounds |
2 |
|
radiography, thoracic |
2 |
|
radiology |
2 |
|
random allocation |
2 |
|
randomized controlled trials |
2 |
|
recurrent esophageal carcinoma |
2 |
|
resection |
2 |
|
retrosternal route |
2 |
|
route of reconstruction |
2 |
|
self-expanding metallic stent |
2 |
|
sepsis |
2 |
|
sports medicine |
2 |
|
squamous cell cancer |
2 |
|
squamous cell carcinoma of the oesophagus |
2 |
|
stent |
2 |
|
stents |
2 |
|
stents - adverse effects |
2 |
|
steroid receptor |
2 |
|
stomach - pathology |
2 |
|
stromal tumor |
2 |
|
subcutaneous tumor xenograft |
2 |
|
surgical |
2 |
|
surgical procedures, minimally invasive |
2 |
|
surgical reconstruction |
2 |
|
therapeutic target |
2 |
|
thoracotomy |
2 |
|
time factors |
2 |
|
tobacco |
2 |
|
tracheal neoplasms - mortality - radiotherapy - secondary |
2 |
|
transhiatal |
2 |
|
transthoracic |
2 |
|
trauma |
2 |
|
treatment |
2 |
|
treatment experience |
2 |
|
tuberous sclerosis. |
2 |
|
tumor markers, biological - isolation & purification |
2 |
|
tumor markers, biological - metabolism |
2 |
|
tumor suppressor protein p53 - metabolism |
2 |
|
tumor suppressor proteins |
2 |
|
ultrastructural |
2 |
|
western world |
2 |
|
wnt |
2 |
|
adenocarcinoma - pathology - surgery |
1 |
|
adenocarcinoma of the esophagogastric junction |
1 |
|
anastomotic leak |
1 |
|
anti-proliferation |
1 |
|
ascites - radiography |
1 |
|
barrett esophagus |
1 |
|
blue nevus |
1 |
|
body weight loss |
1 |
|
cancer genetics |
1 |
|
carcinoma, mucoepidermoid - diagnosis - secondary |
1 |
|
carcinoma, squamous cell - pathology - surgery |
1 |
|
cardia - parasitology |
1 |
|
case report |
1 |
|
cell cytotoxicity |
1 |
|
chemokine (c‑c motif) ligand 5 |
1 |
|
chinese population |
1 |
|
cisplatin resistance |
1 |
|
clinical competence |
1 |
|
computer assisted tomography |
1 |
|
cyclooxygenase 2 |
1 |
|
cyclooxygenase-2 |
1 |
|
data set |
1 |
|
data sharing |
1 |
|
decision-making |
1 |
|
definitive chemoradiotherapy |
1 |
|
delphi consensus study |
1 |
|
diagnosis, differential |
1 |
|
dinoprostone |
1 |
|
double sarcomatoid carcinomas |
1 |
|
ectopic |
1 |
|
epas1 |
1 |
|
esofagectomía |
1 |
|
esofágicas |
1 |
|
esophaegal squamous cell carcinoma |
1 |
|
esophageal diseases - diagnosis |
1 |
|
esophageal diseases - pathology |
1 |
|
esophageal malignancy |
1 |
|
esophageal neoplasms - diagnosis |
1 |
|
esophageal neoplasms - pathology |
1 |
|
esophageal rupture |
1 |
|
esophagectomy - adverse effects - methods - mortality |
1 |
|
esophagectomy - methods - mortality - statistics and numerical data |
1 |
|
esophagogastric junction - surgery |
1 |
|
esophagogastric junction cancer |
1 |
|
esophagoscopy |
1 |
|
esophagoscopy - methods |
1 |
|
esophagus -- cancer -- surgery. |
1 |
|
esófago |
1 |
|
expert consensus |
1 |
|
fam134b |
1 |
|
filariasis |
1 |
|
filariasis - diagnosis |
1 |
|
focus group |
1 |
|
gastric cancer surgery |
1 |
|
gastro-oesophageal junction |
1 |
|
gastroesophageal junction |
1 |
|
guidelines |
1 |
|
hematoma - diagnosis |
1 |
|
heterografts |
1 |
|
histologic grade |
1 |
|
histopathologic type |
1 |
|
immunotherapy |
1 |
|
individual patient data |
1 |
|
individual patient data meta-analysis |
1 |
|
individual patient data network meta-analysis |
1 |
|
insulin-like growth factor binding protein-5 |
1 |
|
international collaboration on cancer reporting |
1 |
|
jk1 |
1 |
|
laparoscopía |
1 |
|
locally advanced gastric adenocarcinoma |
1 |
|
locoregional lymph node metastases |
1 |
|
lumican |
1 |
|
lung - radiography |
1 |
|
lymph node metastases |
1 |
|
lymphangioleiomyomatosis - radiography |
1 |
|
lymphatic metastasis - pathology |
1 |
|
mediastinoscopy |
1 |
|
melanin |
1 |
|
melanocyte |
1 |
|
melanocytes - pathology |
1 |
|
modified delphi consensus |
1 |
|
morbidities |
1 |
|
multidisciplinary treatment |
1 |
|
mutations |
1 |
|
n (regional lymph node classification) |
1 |
|
neoplasias |
1 |
|
nevus, blue - pathology |
1 |
|
nishi classification |
1 |
|
nude-mice |
1 |
|
oesophageal neoplasm |
1 |
|
otorhinolaryngology |
1 |
|
patient care team |
1 |
|
peritoneal diseases - radiography |
1 |
|
pn+ |
1 |
|
postoperative morbidity and mortality |
1 |
|
ppar delta |
1 |
|
prognostication |
1 |
|
quality measures |
1 |
|
quinoline |
1 |
|
quinoline derivatives |
1 |
|
quinolines |
1 |
|
radiography, abdominal |
1 |
|
real-time polymerase chain reaction |
1 |
|
retreg1 |
1 |
|
reverse transcription polymerase chain reaction |
1 |
|
rupture, spontaneous |
1 |
|
siewert classification |
1 |
|
skin neoplasms - pathology |
1 |
|
statistics |
1 |
|
stomach diseases - diagnosis - parasitology |
1 |
|
stomach neoplasms - diagnosis - secondary |
1 |
|
structured report |
1 |
|
surgical quality assurance |
1 |
|
surgical resection |
1 |
|
surrogate endpoint |
1 |
|
t (tumor classification) |
1 |
|
time of diagnosis |
1 |
|
volume-outcome relationship |
1 |
|
worldwide esophageal cancer collaboration (wecc) |
1 |
